News | November 16, 2025
Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Venus Remedies now has 29 active product approvals in Vietnam alone
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
